| Author (study name), year, country | Study setting (n) | Intervention/controlaSample sizebAge (median [IQR], or mean ± SD)cProportion of females, n (%) | Description of intervention and control (where applicable) | Main outcomes of intervention |
|---|---|---|---|---|
| Labreck∞, 2021, USA49 | Antiarrhythmic clinic (1) | a12/9 b† c3 (25%)/4 (44.5%) |
Pharmacy-led outpatient clinic using the AliveCor Kardia Mobile ECG to deliver sotalol loading (electrophysiologist oversight) vs. inpatient sotalol loading (control) | Inpatients administered 120mg twice daily, 88.3% outpatients received this dose (three received different doses at electrophysiologist discretion (n=2), or because of prolonged baseline QT interval (n=1) |
| Finks, 2011, USA48 | Hospital (1) | a36 b75 ± 8.9 dose appropriate or accepted dose adjustment, 78 ± 7.6 partial dose adjustment or no adjustment c† |
Pharmacist assessment of sotalol prescribing for atrial fibrillation patients according to renal function, physician prescribing recommendations made when appropriate | Pharmacist recommendation of drug discontinuation/ dose amendment in 32/36, accepted for 12/32 (appropriate therapy) but not for 20/32 (inappropriate therapy), no effect on all-cause hospital re-admission rates at six months for patients on appropriate therapy (31% vs. 55%, p=0.095) |